Investing.com - Genmab AS reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Genmab AS announced earnings per share of $0.0732 on revenue of $311.27M. Analysts polled by Investing.com anticipated EPS of $0.0716 on revenue of $269.29M.
Genmab AS shares are up 10.62% from the beginning of the year and are trading at $44.98 , down-from-52-week-high.They are under-performing the Nasdaq which is up 14.53% from the start of the year.
Genmab AS shares lost 0.93% in intra-day trade after the report.
Genmab AS follows other major Healthcare sector earnings this month
Genmab AS's report follows an earnings beat by Merck ADR on Thursday, August 5, 2021, who reported EPS of $0.5304 on revenue of $5.77B, compared to forecasts EPS of $0.4897 on revenue of $5.63B.
Hoya Corp had beat expectations on Thursday, July 29, 2021 with second quarter EPS of $1.02 on revenue of $1.44B, compared to forecast for EPS of $0.8576 on revenue of $1.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar